10.1016/j.cbi.2014.10.016 36 LushchakV
AOD 9604 does not suppress appetite the way GLP-1 medications do
Yet, some patients who receive those medications suffer from facial aging
Its pharmacological activators, including oltipraz and bardoxolone methyl, have been shown to ameliorate cognitive deficits and attenuate lipid peroxidation damage in AD models ( 4.3 Immunomodulatory strategies for ferroptosis regulation in Alzheimers disease In Alzheimers disease (AD), ferroptosis is not only characterized by disrupted iron metabolism and lipid peroxidation, but also by the activation of immune cells including microglia, astrocytes, and T lymphocytes
In phase 2 trials, people lost anywhere from 7% to 24% of their body weight in 48 weeks, depending on the dose
And unlike other GLP-1s, it works on just one chemical pathway, which can be harder on the body and may increase side effects like nausea and GI distress, says Dr